NYSE$BDX
Becton Dickinson & Co. · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Reported strong second fiscal quarter results, driven by COVID-19 testing sales and core business growth, while reaffirming fiscal 2021 guidance.
BD (Becton, Dickinson and Company) reported a 15.4% increase in quarterly revenues to $4.9 billion for the second fiscal quarter ended March 31, 2021. This growth was driven by COVID-19 diagnostic revenues of $480 million and strong core business growth. GAAP diluted EPS increased 77.4% year-over-year to $0.94, and adjusted EPS increased 25.1% year-over-year to $3.19. The company reaffirmed its fiscal 2021 revenue growth and adjusted EPS guidance.
- Second fiscal quarter revenues of $4.9 billion grew 15.4% on a reported basis. On a currency-neutral basis, revenues increased 12.2%.
- BD’s COVID-19 testing sales were $480 million, including BD Veritor™ Plus System revenues of $290 million.
- BD’s core growth led by strong growth in Medication Delivery Solutions (up 10.4%), Pharmaceutical Systems (up 15.4%), and Biosciences (up 16.3%) on a reported basis.
- Second fiscal quarter GAAP diluted earnings per share (EPS) increased 77.4% year-over-year to $0.94. Adjusted EPS increased 25.1% year-over-year to $3.19.
Headline financials
Revenue & EPS history
BD · Revenue · Quarterly
$4.91B
Revenue by segment
BD · $2.6B total across 2 segments · Q2 2021
- BD Life Sciences$1.59B+42.5%61.1%
- BD Interventional$1.01B+2.1%38.9%
Forward guidance
The company continues to expect fiscal year 2021 revenues to grow 12% to 14% on an as reported basis and 10% to 12% on a currency-neutral basis. Foreign currency is expected to contribute approximately 200 basis points to revenue growth. The company continues to expect fiscal year 2021 adjusted diluted EPS to be between $12.75 and $12.85.
Tailwinds
- Expects fiscal year 2021 revenues to grow 12% to 14% on an as reported basis.
- Expects fiscal year 2021 revenues to grow 10% to 12% on a currency-neutral basis.
- Foreign currency is expected to contribute approximately 200 basis points to revenue growth.
- Continues to expect fiscal year 2021 adjusted diluted EPS to be between $12.75 and $12.85.
- Adjusted EPS guidance range represents growth of approximately 25% to 26% over fiscal 2020 adjusted diluted EPS of $10.20.
Headwinds
- The COVID-19 pandemic continues to impact the global economy and health care utilization trends.
- Fiscal 2021 outlook includes assumptions of no significant change in utilization or procedure volumes associated with COVID-19 resurgences.
- Potential charges or gains may be recorded during the fiscal year, such as the non-cash amortization of intangible assets.
- Potential charges or gains may be recorded during the fiscal year, such as acquisition-related charges.
- Potential charges or gains may be recorded during the fiscal year spin-off related charges, and certain tax matters.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
-0.9%
Avg return
Earnings day
-0.9%
Avg return
5 days after
-0.5%
Avg return
30 days after
38%
28 / 73 earnings
Positive
+8.9%
Q3 2025
Best reaction
-18.1%
Q2 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | -0.7% | -1.1% | +4.6% | |
| Q1 2026 | -1.3% | +6.5% | -1.2% | |
| Q4 2025 | +0.6% | +7.2% | +10.0% | |
| Q3 2025 | +8.9% | +13.1% | +11.6% | |
| Q2 2025 | -18.1% | -20.3% | -16.7% | |
| Q1 2025 | -6.3% | -5.3% | -5.3% | |
| Q4 2024 | -3.5% | -3.7% | -8.3% | |
| Q3 2024 | +0.3% | -2.3% | +0.6% | |
| Q2 2024 | +0.4% | +1.5% | -0.7% | |
| Q1 2024 | -0.7% | -0.1% | -1.5% | |
| Q4 2023 | -8.3% | -8.8% | -9.2% | |
| Q3 2023 | -2.0% | +1.8% | +0.8% | |
| Q2 2023 | -3.8% | -5.3% | -4.5% | |
| Q1 2023 | -3.3% | -0.4% | -6.7% | |
| Q4 2022 | +4.3% | +1.9% | +13.4% | |
| Q3 2022 | +3.8% | +4.2% | +3.2% | |
| Q2 2022 | +1.7% | -1.4% | -0.5% | |
| Q1 2022 | +4.7% | +7.7% | +7.3% | |
| Q4 2021 | -1.3% | -1.4% | -1.2% | |
| Q3 2021 | -5.4% | -6.3% | +1.2% | |
| Q2 2021 | -4.2% | -3.4% | -3.6% | |
| Q1 2021 | -2.4% | -2.6% | -5.5% | |
| Q4 2020 | -0.1% | +1.5% | +2.5% | |
| Q3 2020 | -9.5% | -10.0% | -17.4% | |
| Q2 2020 | -1.8% | +1.1% | -6.6% | |
| Q1 2020 | -13.7% | -10.3% | -16.4% | |
| Q4 2019 | -3.8% | -6.1% | -0.7% | |
| Q3 2019 | +3.5% | +7.6% | +9.4% | |
| Q2 2019 | -3.0% | -4.1% | +2.6% | |
| Q1 2019 | -1.7% | -2.0% | -0.2% | |
| Q4 2018 | -0.2% | +2.5% | +1.6% | |
| Q3 2018 | -1.1% | -0.8% | +4.7% | |
| Q2 2018 | -2.4% | -3.8% | -2.3% | |
| Q1 2018 | -1.3% | -3.4% | -0.6% | |
| Q4 2017 | +7.9% | +6.3% | +8.8% | |
| Q3 2017 | -1.9% | -2.1% | -0.9% | |
| Q2 2017 | -1.4% | -0.5% | +3.5% | |
| Q1 2017 | +0.2% | -0.1% | +3.2% | |
| Q4 2016 | +4.9% | +7.1% | -0.8% | |
| Q3 2016 | -1.2% | -0.9% | +0.9% | |
| Q2 2016 | +2.0% | — | — | |
| Q1 2016 | -4.9% | — | — | |
| Q4 2015 | +3.8% | — | — | |
| Q3 2015 | -3.2% | — | — | |
| Q2 2015 | +0.7% | — | — | |
| Q1 2015 | +2.4% | — | — | |
| Q4 2014 | -0.2% | — | — | |
| Q3 2014 | -2.8% | — | — | |
| Q2 2014 | -0.4% | — | — | |
| Q1 2014 | +1.8% | — | — | |
| Q4 2013 | +0.5% | — | — | |
| Q3 2013 | -2.1% | — | — | |
| Q2 2013 | +4.1% | — | — | |
| Q1 2013 | +3.2% | — | — | |
| Q4 2012 | -4.3% | — | — | |
| Q3 2012 | -1.1% | — | — | |
| Q2 2012 | +0.0% | — | — | |
| Q4 2011 | -4.6% | — | — | |
| Q1 2012 | +1.2% | — | — | |
| Q3 2011 | -2.6% | — | — | |
| Q2 2011 | -1.0% | — | — | |
| Q1 2011 | -0.5% | — | — | |
| Q4 2010 | +2.0% | — | — | |
| Q3 2010 | +1.6% | — | — | |
| Q2 2010 | -2.6% | — | — | |
| Q1 2009 | +0.5% | — | — | |
| Q1 2010 | -1.4% | — | — | |
| Q4 2007 | -1.2% | — | — | |
| Q2 2009 | -1.2% | — | — | |
| Q4 2009 | -1.2% | — | — | |
| Q3 2009 | +2.5% | — | — | |
| Q3 2008 | +2.5% | — | — | |
| Q4 2008 | +2.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro